Welcome to LookChem.com Sign In|Join Free

CAS

  • or
FMOC-GLU(OTBU)-OSU is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

101214-22-6

Post Buying Request

101214-22-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

101214-22-6 Usage

Chemical Properties

White powder

Check Digit Verification of cas no

The CAS Registry Mumber 101214-22-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,2,1 and 4 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 101214-22:
(8*1)+(7*0)+(6*1)+(5*2)+(4*1)+(3*4)+(2*2)+(1*2)=46
46 % 10 = 6
So 101214-22-6 is a valid CAS Registry Number.

101214-22-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name FMOC-GLU(OTBU)-OSU

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:101214-22-6 SDS

101214-22-6Downstream Products

101214-22-6Relevant articles and documents

Synthesis and structural characterization of triple-helical peptided which mimic the ligand binding site of the human macrophage scavenger receptor

Hojo, Hironobu,Akamatsu, Yoshiko,Yamauchi, Kiyoshi,Kinoshita, Masayoshi,Miki, Shunji,Nakamura, Yu

, p. 14263 - 14274 (1997)

A synthetic method for triple-helical peptides was developed. Peptides with and without glutamic acid a-thioester at their N-termini are prepared by the solid-phase method. These peptides are crosslinked at their N-termini one by one to generate trimeric peptides using the activation of the thioester group by silver ions. This method was applied to the synthesis of model peptides, which mimic the binding site of modified low density lipoprotein (LDL) in the human scavenger receptor (SR). These models possessed different spacers, which connect the peptide chains and the crosslinking site. CD and DSC analysis of the peptides revealed that spacer length has a critical effect on the stability of the triple helix.

Site-Specific Incorporation of Multiple Thioamide Substitutions into a Peptide Backbone via Solid Phase Peptide Synthesis

Yang, Jinhua,Wang, Changliu,Yao, Chaochao,Chen, Chunqiu,Hu, Yafang,He, Guifeng,Zhao, Junfeng

, p. 1484 - 1494 (2020/01/02)

Among various peptide modification strategies, thioamide substitution by replacing the carbonyl oxygen atom of an amide bond with a sulfur atom constitutes an invaluable tool for chemical biology, for use in peptide drug discovery and protein structure-fu

ANTI-CD40 ANTIBODY DRUG CONJUGATES

-

Paragraph 00191, (2019/06/17)

Provided herein are anti-CD40 antibody drug conjugates comprising a radical of Formula (I), wherein R1, R2, and R3 are as defined herein. Further provided are anti-CD40 antibody drug conjugates of Formula (II), wherein Z, R, AA1, AA2, AA3, m, p, q, n, w, R1, R2, and R3 are as defined herein. Further provided are pharmaceutical compositions and kits thereof, and methods of using same.

ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF

-

Paragraph 0585; 0586, (2019/11/28)

Provided herein are antibodies and antigen-binding fragments that bind MSR1 and methods of use thereof. According to certain embodiments, the antibodies bind human MSR1 with high affinity. In certain embodiments, the antibodies bind MSR1 without blocking, or blocking less than 90%, of modified LDL binding to MSR1. In some embodiments, the antibodies bind cell surface expressed-MSR1 and are internalized. The antibodies of the invention may be fully human antibodies. The invention includes anti-MSR1 antibodies, or antigen-binding fragments thereof, conjugated to drugs or therapeutic compounds.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 101214-22-6